Friday, AstraZeneca Plc AZN released high-level results of the ADRIATIC Phase 3 trial of Imfinzi monotherapy and Imfinzi plus Imjudo versus placebo in the treatment of 730 patients with limited-stage small cell lung cancer (LS-SCLC) who had not progressed following concurrent chemoradiotherapy (cCRT).
The data showed Imfinzi (durvalumab) demonstrated a statistically significant and clinically meaningful improvement in the dual primary endpoints of overall survival (OS) and progression-free survival (PFS) compared to placebo.
Related Content: AstraZeneca Says Lynparza/Imfinzi Combo Shows Strong Clinical Benefit Vs. Chemotherapy In Endometrial Cancer.
Small cell lung cancer is a highly aggressive form of cancer that typically recurs and progresses rapidly despite initial response to chemotherapy and radiotherapy, with only 15% to 30% of patients alive five years after diagnosis, AstraZeneca said.
The safety profile for Imfinzi was consistent with its known profile, and no new safety signals were identified.
The second experimental arm testing the efficacy of Imjudo (tremelimumab) added to Imfinzi as a secondary endpoint remains blinded and will continue to the next planned analysis.
Imfinzi is approved in the US, EU, Japan, China, and many other countries for extensive-stage SCLC (ES-SCLC) based on the CASPIAN Phase 3 trial.
Imfinzi is also the only approved immunotherapy and the global standard of care in the curative-intent setting of unresectable, Stage III non-small cell lung cancer in patients whose disease has not progressed after CRT based on the PACIFIC Phase 3 trial.
Price Action: AZN shares are down 0.23% at $67.18 on the last check Friday.
Photo via Wikimedia Commons
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
